Brazilian Health Regulatory Agency (ANVISA) has granted approval for Telix Pharmaceuticals’ Illuccix, a prostate cancer imaging agent. Illuccix claims to be the first prostate-specific membrane ...

MELBOURNE, Australia and INDIANAPOLIS, March 13, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that it has developed and validated a ...

MELBOURNE, Australia and INDIANAPOLIS, March 13, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that it has developed and validated ...

No-moat Telix Pharmaceuticals’ 2024 revenue rose 56% to AUD 783 million, in line with our forecast. Practically all revenue is attributable to US sales of Illuccix, a diagnostic tool for ...

The Telix Pharmaceuticals Ltd (ASX: TLX) share price is racing higher on Friday morning. At the time of writing, the pharmaceutical company's shares are up 13% to a record high of $30.00.

Telix Pharmaceuticals (ASX:TLX) has won marketing approval for its prostate cancer imaging agent in Brazil, marking the company’s first foray into the South American market. The Brazilian Health ...

Australia-based radiopharmaceutical company Telix Pharmaceuticals has created a new radionuclide generator that could facilitate the commercial supply of lead-212 isotope-based therapies.